Clinical trials: Myeloma-Multiple
Multiple Myeloma
Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma
This Phase 3, 2-arm, randomized, active comparator-controlled, open-label, multicenter study will compare the efficacy and health-related quality of life (HR-QoL) and assess the safety of selinexor plus bortezomib (Velcade) plus…
- Trial name
- BOSTON (NCT03110562)
- Testing
- Selinexor, Bortezomib, Dexamethasone
- Where
- 157 sites in United States, Australia and 19 more
- Volunteers
- 402 people
- Sponsor
- Karyopharm Therapeutics Inc
Relapsed/Refractory Multiple Myeloma
A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
The main purpose of this study is to measure the efficacy (Myeloma response) of subcutaneous (SC) isatuximab treatment in combination with carfilzomib and dexamethasone in adult participants with RRMM having received 1 to 3 prior…
- Trial name
- IZALCO (NCT05704049)
- Testing
- Isatuximab, Carfilzomib, Dexamethasone
- Where
- 23 sites in Australia, Brazil and 5 more
- Volunteers
- 118 people
- Sponsor
- Sanofi
Lymphoma, Non-Hodgkin, Multiple Myeloma
A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease
The purpose of this study is to evaluate of the study of different CNTO 328 doses and schedules and to see if CNTO 328 has any effect on Non-hodgkin's Lymphoma, Multiple Myeloma or Castleman's disease.
- Conditions
- Lymphoma, Non-Hodgkin, Multiple Myeloma, Giant Lymph Node Hyperplasia
- Trial name
- NCT00412321
- Testing
- CNTO 328
- Where
- 9 sites in United States
- Volunteers
- 67 people
- Sponsor
- Centocor, Inc.
Multiple Myeloma
A Safety Study of SGN-CD48A in Patients With Multiple Myeloma
This study will test the safety and activity of SGN-CD48A in patients with multiple myeloma. SGN-CD48A will be given on Days 1, 8, and 15 of a 28-day cycle. Prior to protocol amendment 2, SGN-CD48A was given every 3 weeks.
- Trial name
- NCT03379584
- Testing
- SGN-CD48A
- Where
- 6 sites in United States
- Volunteers
- 14 people
- Sponsor
- Seagen Inc.
Relapsed and Refractory Multiple Myeloma
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
- Trial name
- NCT03029234
- Testing
- Dexamethasone, Carfilzomib
- Where
- 17 sites in China
- Volunteers
- 126 people
- Sponsor
- Amgen
Multiple Myeloma
A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma
The main aims of this study are to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp alfa.
- Trial name
- iinnovate-2 (NCT05556616)
- Testing
- Modakafusp alfa, Lenalidomide, Bortezomib
- Where
- 21 sites in United States, Belgium and 2 more
- Volunteers
- 15 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Relapsed and Refractory Multiple Myeloma
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.
- Trial name
- NCT04155749
- Testing
- anitocabtagene-autoleucel
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kite, A Gilead Company
Multiple Myeloma and Plasma Cell Neoplasm
AE-941 in Treating Patients With Relapsed or Refractory Multiple Myeloma
RATIONALE: AE-941 may help to slow the growth of multiple myeloma. PURPOSE: Phase II trial to study the effectiveness of neovastat in treating patients who have relapsed or refractory multiple myeloma.
- Trial name
- NCT00022282
- Testing
- shark cartilage extract AE-941
- Where
- Canada
- Sponsor
- AEterna Zentaris
Advanced Hematologic Malignancies
How [14C]-DSP-5336 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Patients With Advanced Blood Cancers
The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after…
- Trial name
- NCT07444268
- Testing
- DSP-5336, [14C]-DSP-5336
- Where
- 2 sites in United States
- Volunteers
- 8 people
- Sponsor
- Sumitomo Pharma America, Inc.
Multiple Myeloma
Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma
This study comprises of a dose-escalation and dose expansion phase and will determine the maximum tolerated dose of oral Panobinostat on a continuous schedule in adult in combination with bortezomib.
- Trial name
- NCT00532389
- Testing
- LBH589
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL)
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety.
- Conditions
- Relapsed or Refractory Multiple Myeloma (RRMM), Diffuse Large B Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML)
- Trial name
- NCT04824794
- Testing
- GEN3014, Daratumumab
- Where
- 52 sites in United States, Australia and 18 more
- Volunteers
- 130 people
- Sponsor
- Genmab
Multiple Myeloma (MM)
A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)
This study is focused on participants with Newly Diagnosed Multiple Myeloma (NDMM) who are eligible for high dose chemotherapy followed by Autologous Stem Cell Transplantation (ASCT).
- Trial name
- LINKER-MM8 (NCT07428369)
- Testing
- Linvoseltamab, Bortezomib, Lenalidomide
- Sponsor
- Regeneron Pharmaceuticals
Multiple Myeloma
A Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
This study is a single-arm, open-lable, phase I/II study to evaluate the efficacy and safety of GC012F in subjects with relapsed/refractory multiple myeloma.
- Trial name
- DURGA-3 (NCT06235229)
- Testing
- GC012F
- Where
- 10 sites in China
- Volunteers
- 110 people
- Sponsor
- Gracell Biotechnologies (Shanghai) Co., Ltd.
Multiple Myeloma
A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma
This multicenter, open-label, dose-escalating study will assess the safety and efficacy of DFRF4539A in patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT01432353
- Testing
- DFRF4539A
- Where
- 8 sites in United States
- Volunteers
- 39 people
- Sponsor
- Genentech, Inc.
Multiple Myeloma
Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM
This is an open-label Phase 1/2a study which will enroll patients that have relapsed or relapsed-refractory multiple myeloma to combination regimens of melflufen with currently approved agents.
- Trial name
- ANCHOR (NCT03481556)
- Testing
- Melphalan flufenamide (Melflufen), Dexamethasone, Bortezomib
- Where
- 16 sites in United States, Czechia and 2 more
- Volunteers
- 56 people
- Sponsor
- Oncopeptides AB
Multiple Myeloma
A Non-interventional Study of Melphalan Flufenamide (Melflufen) (Pepaxti®) and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma (R/RMM)
Multiple myeloma is the second most common hematologic malignancy in adults and despite the new therapies that have been developed in the last decades it remains incurable.
- Trial name
- MARINA (NCT07559799)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- iOMEDICO AG
Relapsed or Refractory Multiple Myeloma
A Ph1/2 Study of EMB-06 in Participants With Relapsed or Refractory Myeloma
The primary purpose of this study is to identify the recommended Phase 2 dose(s) (RP2Ds) and schedule assessed to be safe for EMB-06 and to characterize the safety and tolerability of EMB-06 at the RP2Ds.
- Trial name
- NCT04735575
- Testing
- EMB-06
- Where
- 10 sites in Australia, China
- Volunteers
- 40 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Multiple Myeloma
Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma
The purpose of this study is to evaluate time to progression, overall survival, response rate and safety for the two open-label treatment groups; DOXIL/CAELYX in combination with VELCADE vs. VELCADE monotherapy.
- Trial name
- NCT00103506
- Testing
- Bortezomib (VELCADE), Doxorubicin hydrochloride (DOXIL/CAELYX)
- Where
- 108 sites in United States, Argentina and 15 more
- Volunteers
- 646 people
- Sponsor
- Janssen Research & Development, LLC
Multiple Myeloma in Relapse, Refractory Multiple Myeloma
Combination Study of Pomalidomide, Marizomib, and Low-Dose Dexamethasone in Relapsed and Refractory Multiple Myeloma
This is a Phase 1 clinical trial to evaluate a new combination of drugs for the treatment of relapsed or refractory (drug-resistant) multiple myeloma.
- Conditions
- Multiple Myeloma in Relapse, Refractory Multiple Myeloma, Multiple Myeloma
- Trial name
- NCT02103335
- Testing
- pomalidomide, marizomib, low-dose dexamethasone
- Where
- 6 sites in United States, Australia
- Volunteers
- 38 people
- Sponsor
- Celgene
Multiple Myeloma
A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma
The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).
- Trial name
- NCT05347485
- Testing
- Cilta-cel, Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)
- Where
- 18 sites in United States
- Volunteers
- 86 people
- Sponsor
- Janssen Scientific Affairs, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.